Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer

BACKGROUND: Mature progression-free survival (PFS) data from the phase III J-ALEX study showed superiority for alectinib versus crizotinib [hazard ratio (HR) 0.37, 95% confidence interval (CI) 0.26-0.52; median PFS 34.1 versus 10.2 months, respectively] in advanced ALK (anaplastic lymphoma kinase)-p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hotta, K., Hida, T., Nokihara, H., Morise, M., Kim, Y.H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Shukuya, T., Nakagawa, K., Mitsudomi, T., Yamamoto, N., Asakawa, T., Yoshimoto, T., Takata, S., Tamura, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434408/
https://www.ncbi.nlm.nih.gov/pubmed/35843080
http://dx.doi.org/10.1016/j.esmoop.2022.100527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434408/
https://www.ncbi.nlm.nih.gov/pubmed/35843080
http://dx.doi.org/10.1016/j.esmoop.2022.100527

Ejemplares similares